Intellipharmaceutics International reported the availability of the 25 and 35 mg strengths of its generic Focalin XR (dexmethylphenidate hydrochloride extended-release) capsules in the US for the treatment of attention deficit hyperactivity disorder. This market launch was initiated by the company's US marketing partner, Par Pharmaceutical. In conjunction with the launch, the US Food and Drug Administration has awarded its final approval for Par's abbreviated new drug application (ANDA) for its generic Focalin XR capsules in the 5, 10, 15, 20, 25, 30, 35 and 40 mg strengths. As the first filer of an ANDA for generic Focalin XR in the 25 and 35 mg strengths, Par will have 180 days of US generic marketing exclusivity for those strengths and Intellipharmaceutics International will receive quarterly profit-share payments on Par's US sales of generic Focalin XR.